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Tissue turnover of collagen type I, III and
elastin is elevated in the PCLS model of IPF
and can be restored back to vehicle levels
using a phosphodiesterase inhibitor
Niels Ulrik Brandt Hansen1,2* , Morten Asser Karsdal1,2, Sarah Brockbank3, Simon Cruwys3, Sarah Rønnow1
and Diana Julie Leeming1
Abstract
Background: The aim of this study was to develop and validate a model for pulmonary fibrosis, using ex vivo tissue
cultures of lungs from bleomycin treated animals, enabling the investigation of fibrosis remodeling using novel
biomarkers for the detection of ECM protein fragments. The combination of in vivo and ex vivo models together
with ECM remodeling markers may provide a translational tool for screening of potential treatments for IPF.
Methods: Twenty female Sprague-Dawley rats, twelve weeks of age, were administrated either two doses of
bleomycin (BLM) (n = 14) or saline (n = 6) I.T., two days apart. Ten rats were euthanized at day seven and the
remaining ten rats at day fourteen, after the last dose. Precision-cut lung slices (PCLS) were made and cultured
for 48 h.
Ten female Sprague-Dawley rats, twelve weeks of age, were administrated either two doses of BLM (n = 7) or
saline (n = 3) I.T., two days apart. The rats were euthanized fourteen days after the last dose. PCLS were made and
cultured for 48 h in: medium, medium+ 100 μM IBMX (PDE inhibitor), or medium + 10 μM GM6001 (MMP inhibitor).
Turnover of type I collagen (P1NP, C1M), type III collagen (iP3NP, C3M) and elastin degradation (ELM7) was measured
in the supernatant of the cultured PCLS.
Results: P1NP, C1M, iP3NP, C3M and ELM7 were significantly increased in supernatants from BLM animals (P≤ 0.05 –
P≤ 0.0001) when compared to controls. P1NP, C1M, iP3NP, C3M and ELM7 were significantly increased in supernatants
from day seven BLM animals compared to day fourteen BLM animals (P≤ 0.05 – P≤ 0.0001). P1NP, C1M, iP3NP, C3M
and ELM7 were significantly decreased when adding IBMX to the culture medium of fibrotic lung tissue (P≤ 0.05 – P≤
0.0001). C1M, C3M and ELM7 were significantly decreased when adding GM6001 to the culture medium (P≤ 0.05 –
P≤ 0.0001).
Sirius Red and Orcein staining confirmed the presence of collagen and elastin deposition in the lungs of the animals
receiving BLM.
Conclusions: The protein fingerprint technology allows the assessment of ECM remodeling markers in the BLM PCLS
model. By combining in vivo, ex vivo models and the protein fingerprint technology in the fibrotic phase of the model,
we believe the chance of translation from animal model to human is markedly increased.
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Background
Idiopathic interstitial pneumonias are a diverse group of
diseases characterized by fibrosis and inflammation, of
which idiopathic pulmonary fibrosis (IPF) is the most
common type. The etiology of the disease is unknown
but it is believed to be an interplay between genetic pre-
dispositions and environmental causes, such as pollution
and cigarette smoke [1]. The hallmark of fibroprolifera-
tive diseases can be described as a dysregulated wound
healing, leading to a shift in the balance of extracellular
matrix (ECM) remodeling and accumulation of matrix
components and end stage fibrosis with loss of function
of the affected organ. The total ECM turnover is in-
creased in IPF, meaning that both formation and degrad-
ation of proteins is upregulated, but the net result is
matrix deposition. The formation and degradation of
matrix proteins generate protein fragments, which are
released into circulation, forming neoepitopes that may
be measured as biomarkers. A paper just published in
The Lancet describes how novel biomarkers of the ECM
were able to separate fast progressing IPF patients from
stable IPF patients, while some of the markers were also
strongly predictive of overall survival [2]. The ECM has
gained a lot of attention during the last decades and it is
now recognized as a structure with multiple functions
such as cell support, cytokine activation and signaling
purposes [3]. It is known to be important for the pheno-
type and survival of cells, e.g. orientation of collagen can
critically regulate cell and tissue behavior [4–6]. More-
over the ECM can serve as a storage site for multiple
soluble/secreted cytokines and growth factors, thereby
functioning as a repository. These factors can be re-
leased into the microenvironment upon matrix degrad-
ation by matrix metalloproteinases (MMPs) [7, 8]. The
accumulation of ECM proteins also affects the rigidity of
the matrix causing the matrix to become stiff. This stiff-
ness affects the communication and signaling of the
matrix and hence results in the thickening of the inter-
stitium in the alveoli, which leads to less O2 uptake and
shortness of breath. The stiffness has also been shown
to affect myofibroblast activation which ultimately leads
to more matrix deposition and rigidity, thus creating a
positive feedback loop and linking matrix architecture
and composition with cell phenotype [9–11].
The precision cut lung slice model using IPF tissue en-
ables the possibility of studying the fibrotic processes in
a multicellular system in which cell-cell, cell-ECM inter-
actions and opened alveoli are preserved, thus maintain-
ing the 3D structure seen in vivo [12, 13]. The
importance of the interplay between the cells and the
microenvironment is very well described within the can-
cer field. Important factors such as the presence of all
the different cell types, structural support from the
ECM, signaling (e.g. via transmembrane receptors) and
cytoskeletal and chromatin organization are some of the
highlighted features. In order to get full insight into the
biology of normal and diseased tissue, it is vital to create
in vivo-like models for therapeutic testing to get the full
context of the effects [14–17]. In addition, the PCLS
model enables the study of a heterogeneous matrix,
which provides an in vivo-like environment with mini-
mum alterations of the natural conditions in order to
study cell behavior and function. This is a very crucial
matter when testing potential therapies [3]. Due to the
importance and influence of the matrix in IPF, we used
the fit for purpose Precision-Cut Lung Slice (PCLS)
model [18] using in vivo BLM treated lung tissue com-
bining it with a novel Protein Fingerprint biomarker
technology for the assessment of the ECM remodeling.
We have chosen two compounds, IBMX (non-selective
phosphodiesterase inhibitor) and GM6001 (pan MMP
inhibitor), as they have been shown to have a positive ef-
fect on remodeling biomarkers and are non-toxic in
ex vivo models of the liver and cartilage [12, 19, 20]. The
treatments were applied in what is generally accepted as
the fibrotic phase, at day 14 following BLM administration.
We combined the rodent PCLS model with in vivo
BLM treated lung tissue and the novel Protein Finger-
print biomarker technology for the assessment of the
ongoing ECM protein remodeling. The aims of this
study were to design and validate a model for screening
of potential therapies for IPF.
Methods
Reagents
All reagents were standard high-quality chemicals from
either Merck or Sigma-Aldrich. The culture medium
William’s Medium E was from Gibco (Life Technolo-
gies), while AlamarBlue assay was from AbD Serotec.
Animal experiment
Thirty female Sprague-Dawley rats, aged twelve weeks,
were used for two experiments and were housed at the
animal facilities at Nordic Bioscience, Denmark. The ex-
periments were approved by the Animal Ethics Commit-
tee of the Danish Ministry of Justice (2011/561-2003,
2012-15-2934-00467). The rats were housed in standard
cages, with bedding and nest material at 18-22 °C and
fed with standard pellet diet and tap water ad libitum.
The rats were kept under conditions of a 12 h light/dark
cycle. Pulmonary fibrosis was induced by I.T. installation
of two doses of BLM (0.25 ml/kg), two days apart. The
BLM was sprayed into the lungs of the rats using the
MicroSprayer® Aerosolizer with the FMJ-250 High Pres-
sure Syringe (Penn-Century, PA, USA). In the first ex-
periment fourteen animals were given BLM and six
animals were given saline. Ten animals were euthanized
seven days after the last BLM/saline dose, and ten
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animals were euthanized fourteen days after the last
BLM/saline dose.
In the second experiment seven animals were given
BLM and three animals were given saline, two days
apart. The animals were euthanized fourteen days after
last BLM/saline dose.
Ex vivo experiments
Prior to euthanization of the rats, the animals were anes-
thetized and a small catheter was surgically inserted into
the trachea. After euthanization, the catheter was used
to fill the lungs with a low temperature gelling agarose
in order to keep the lungs dilated. The lungs were ex-
cised and stored in ice-cold Krebs-Henseleit buffer con-
taining 25 mM glucose, 10 mM HEPES and 25 mM
NaHCO3. PCLS were prepared from the lungs using a
TSE Krumdieck tissue slicer MD 4000 as previously de-
scribed [18]. The PCLS were cultured for 48 h, as longer
incubation would affect cell viability, at 37 °C under car-
bogen atmosphere in sterile 48 well plates containing
300 μl William’s Medium E containing 25 mM glucose,
50 μg/mL gentamicin and the respective treatment.
Treatments used for the ex vivo model were 100 μM
IBMX (Sigma-Aldrich, Denmark), a non-selective PDE
inhibitor, and 10 μM GM6001 (Sigma-Aldrich, Denmark),
a pan MMP inhibitor. After the culturing period the su-
pernatants were collected and stored at -20 °C until use.
Cell viability measured by AlamarBlue
AlamarBlue is a sterile non-toxic aqueous oxidation-
reduction indicator that yields colorimetric changes and
a fluorescent signal in response to metabolic activity.
The active compound, resazurin, is an oxidation-reduction
indicator that changes from the oxidized non-fluorescent
form to the reduced fluorescent form according to the via-
bility and proliferating activity of cells [21]. In short,
300 μL 10 % AlamarBlue was added to each well of the
microtiter plate containing PCLS and incubated for
90 min at 37 °C while shaking. The results were measured
by an ELISA reader at 540-590 nm.
ELISA measurements
The P1NP ELISA is specific for the N-terminal pro-
peptide of type I collagen. It is a marker of collagen type
I formation as the pro-peptide is cleaved off the mature
protein prior to fibril assembly [22]. The C1M marker is
specific for a fragment generated by MMP-2, -9 and -13,
and hence reflects MMP generated degradation of colla-
gen type I [23]. The iP3NP marker is specific for an in-
ternal epitope of the N-terminal pro-peptide of type III
collagen, which reflects the formation of collagen type
III (unpublished). The C3M marker is specific for the a
neo-epitope generated by MMP-9, and reflects the deg-
radation of type III collagen [24]. The ELM7 marker is
specific to a neo-epitope generated by MMP-7 degrad-
ation of elastin [25]. All the above ELISA assays are de-
veloped and validated by Nordic Bioscience (see
references for the technical papers). The markers were
assessed in the supernatants of the cultured PCLS, i.e.
the release of the epitopes into the supernatants.
Histological analysis
Lung tissue were fixed in cold 4 % neutral formalin di-
luted in phosphate-buffered saline at 4 °C and processed
for paraffin embedding using a Sakura Tissue Tek VIP 5
Jr. Tissue Processor and cut on a microtome in 5 μm-
thick slides.
Sirius Red
The slides were deparaffinized, rehydrated and incubated
with Weigert’s Haematoxylin for 8 min, washed in water,
and then incubated with a 0.1 % Sirius Red solution dis-
solved in aqueous saturated picric acid for 1 h, washed
in water, dehydrated and mounted with PERTEX®. Pictures
were taken with an Olympus BX60 microscope mounted
with an Olympus DP71 camera at 4x magnification.
Orcein stain
The slides were deparaffinized, rehydrated and incubated
with Acid Orcein Solution for 30 min, washed in water,
and then incubated with Mayer’s Haematoxylin Solution
for 30 s, washed in water, dehydrated and mounted with
PERTEX®. Pictures were taken with an Olympus BX60
microscope mounted with an Olympus DP71 camera at
40x magnification.
Statistical analyses
Results are shown as mean ± standard error of mean
(SEM). Differences between mean values were com-
pared by nonparametric Mann-Whitney’s t-test for
two-tailed observations. All statistical analyses were
performed in GraphPad Prism software v.6 (GraphPad
Software, San Diego, CA). P values less than 0.05 were
considered significant.
Results
ECM remodeling is increased in fibrotic lung
There was a 10-fold increase of type I collagen forma-
tion (P1NP) in the conditioned medium from BLM ani-
mals versus saline control animals at day 7 termination
in the PCLS model (p < 0.0001) (Fig. 1a). Moreover
P1NP was significantly increased in the conditioned
medium from BLM animals at day 14 compared to day
14 saline controls (p = 0.0008), but significantly de-
creased when compared to day 7 BLM animals (p <
0.0001) (Fig. 1a).
There were increased levels of type I collagen degrad-
ation (C1M) in the conditioned medium from BLM
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animals versus saline control animals in the PCLS model
at day 7 termination (p = 0.016) (Fig. 1b). In addition,
C1M was significantly decreased in the conditioned
medium of BLM animals terminated at day 14 when
compared to conditioned medium from day 7 termin-
ation in the PCLS model (p = 0.015) (Fig. 1b).
Type III collagen formation (iP3NP) was significantly
increased in the conditioned medium from BLM animals
when compared to saline control animals terminated at
day 7 in the PCLS model (p = 0.0001) (Fig. 1c). The
levels of iP3NP were significantly decreased in the con-
ditioned medium from BLM animals terminated at day
14 when compared to the conditioned medium from
BLM animals terminated day 7 in the PCLS model (p =
0.017), but still significantly elevated compared to day 14
saline controls (p = 0.0005) (Fig. 1c).
There were a 15-fold increase in the levels of collagen
type III degradation (C3M) in the conditioned medium
of BLM animals when compared to saline control ani-
mals terminated at day 7 (p < 0.0001) in the PCLS model
(Fig. 1d). The levels of C3M were significantly decreased
in the conditioned medium from BLM animals termi-
nated at day 14 when compared to the conditioned
medium from BLM animals terminated at day 7 in the
PCLS model (p = 0.0008), but still significantly elevated
compared to day 14 saline controls (p < 0.0001) (Fig. 1d).
Levels of MMP-7 generated elastin fragments (ELM7)
were significantly increased the conditioned medium
from BLM animals when compared to saline control an-
imals terminated at day 7 (p = 0.0002) in the PCLS
model (Fig. 1e). The levels of ELM7 were significantly
decreased in the conditioned medium from BLM ani-
mals terminated at day 14 when compared to the condi-
tioned medium from BLM animals terminated at day 7
(p < 0.0001) but still significantly elevated compared to
day 14 saline controls (p < 0.0001) (Fig. 1e).
Lung ECM remodeling can be differentially modulated by
intervention
There were significantly increased levels of type I colla-
gen formation (P1NP) in the conditioned medium from
BLM animals when compared to saline control animals
(p = 0.013) in the PCLS model (Fig. 2a). Adding IBMX
to the medium significantly decreased the levels (p <
0.05), while adding GM6001 had no significant effect
(Fig. 2a). There were significantly increased levels of type
I collagen degradation (C1M) in the conditioned medium
from BLM animals when compared to saline control ani-
mals (p = 0.014) in the PCLS model (Fig. 2b). Adding
IBMX to the medium significantly decreased the levels
(p < 0.0001), and the same was seen when adding
GM6001 (p < 0.0001) to the medium (Fig. 2b).
**** ****
***
**
*** *
***
**** **
****
*** ****
****
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c d e
Fig. 1 Levels of N-terminal propeptide of collagen type I (a), MMP-2, 9 and 13 generated fragments of collagen type I (b), N-terminal propeptide
of collagen type III (c), MMP-9 generated fragments of collagen type III (d) and MMP-7 generated fragments of elastin (e) in the supernatants of
the PCLS model after 48 h of culturing from animals euthanized seven days after last BLM or vehicle dosing and animals euthanized 14 days after
the last dosing. w/o: Williams E medium without intervention. Significance level: *p < 0.05, **p < 0.01, *** p < 0.001, ****p < 0.0001
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Significantly increased levels of collagen type III for-
mation (iP3NP) were seen in the conditioned medium
from BLM animals when compared to saline control an-
imals (p < 0.05) in the PCLS model (Fig. 2c). Adding
IBMX to the medium significantly decreased the levels
(p = 0.003), while adding GM6001 had no significant ef-
fect (Fig. 2c).
Significantly increased levels of MMP-9 degraded
collagen type III (C3M) were observed in the condi-
tioned medium from BLM treated animals when
compared to saline control animals (p < 0.0001) in
the PCLS model (Fig. 2d). There was a 5-fold in-
crease in the supernatant from the BLM treated ani-
mals, which could be significantly decreased by
adding IBMX (p < 0.0001) to the medium, while
GM6001 (p < 0.0001) was able to decrease the levels
below vehicle (Fig. 2d).
Levels of MMP-7 generated fragments of elastin
(ELM7) were significantly elevated in the conditioned
medium from BLM treated animals when compared to
vehicle treated animals (p < 0.0001) in the PCLS model
(Fig. 2e). It was seen that adding IBMX (p = 0.02) and
GM6001 (p = 0.015) were able to significantly decrease
the ELM7 levels.
Viability was sustained in the PCLS
The viability of the PCLS was measured by AlamarBlue
at baseline and after 48 h of culturing. Culturing for
48 h or adding IBMX or GM6001 to the lung slices had
no effect on metabolic activity (small decrease, not sig-
nificant) (Fig. 3).
Histology
Sirius Red staining was performed on the lung tissue. It
was evident that collagen deposition was present in the
lungs of the animals euthanized 7 and 14 days after last
BLM dose compared to the saline control animals
(Fig. 4). In addition, an Orcein Elastin Stain was per-
formed on the lung tissue, and showed a higher presence
of elastin fibers in the lungs of the animals euthanized 7
and 14 days after last BLM dose compared to the saline
control animals (Fig. 5). The Orcein stain also clearly
shows that the tissue sections coming from BLM rats
are more nucleated.
Discussion
This is, to our knowledge, the first study to evaluate the
fibrotic processes in the in vivo-like environment of the
ex vivo PCLS system using novel formation and
* * *****
*** ******** *****
a b
c d e
Fig. 2 Levels of N-terminal propeptide of collagen type I (a), MMP-2, 9 and 13 generated fragments of collagen type I (b), N-terminal propeptide
of collagen type III (c), MMP-9 generated fragments of collagen type III (d) and MMP-7 generated fragments of elastin (e) in the supernatant of
the PCLS model after 48 h of culturing from animals euthanized fourteen days after last BLM or vehicle dosing. w/o: Williams E medium without
any intervention; IBMX: Williams E medium + 100 μM IBMX; GM6001: Williams E medium + 10 μM GM6001. Black bars; slices from vehicle rats. Grey
bars; slices from BLM-treated rats. Significance level: *p < 0.05, **p < 0.01, ****p < 0.0001
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Fig. 3 AlamarBlue was investigated as a measure of metabolic activity in fibrotic and control lung slices. a) Left graph depicts the metabolic activity in
lung slices coming from control and BLM animals euthanized after 7 days, before and after 48 h of cultivation. Right graph depicts the metabolic
activity in lung slices coming from control and BLM animals euthanized after 14 days, before and after 48 h of cultivation. b) The metabolic activity in
lung slices coming from control and BLM animals euthanized after 14 days, before and after 48 h of cultivation. w/o: Williams E medium without any
intervention; IBMX: Williams E medium+ 100 μM IBMX; GM6001: Williams E medium + 10 μM GM6001
Fig. 4 Representative pictures of Sirius Red staining performed on lung tissue from saline control and BLM treated animals. The left section is
slides from animals euthanized 7 days after last BLM or saline dose, while the right section is slides from animals euthanized 14 days after last
BLM or saline dose. Slides from BML treated animals are depicted in the upper row, while slides from saline treated animals are depicted in the
lower row. Pictures were taken at 4x magnification, and the black scale bar in the lower right corner of each picture indicates 1000 μm
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degradation markers of the ECM to investigate fibrosis
remodeling. The animals used for the PCLS model were
treated with BLM in vivo to induce a disease pattern re-
sembling the IPF seen in human. The PCLS were then
cultured in an ex vivo setup and the release of formation
and degradation epitopes into the supernatant were
assessed by ELISA based on monoclonal antibodies.
The highlighted results were: 1) significant differences
were seen in the biomarkers levels between saline and
BLM treated animals, 2) biomarker levels were inhibited
by adding a phosphodiesterase inhibitor or a multiple
MMP inhibitor to the culture medium, and 3) levels of
the biomarkers decreased with increasing time between
last in vivo BLM dosing and termination point.
Jenkins et al. recently published a study, in which they
evaluated eleven different ECM biomarkers developed
by Nordic Bioscience in the PROFILE IPF cohort [2].
Seven of these novel neoepitope biomarkers differed sig-
nificantly in serum from patients diagnosed with IPF
when compared to controls. In addition six of the neoe-
pitope biomarkers were predictive of overall survival of
the IPF patients. This paper clearly shows that the ECM
remodeling taking place during the pathogenesis of IPF
can be assessed by ECM biomarkers. In our rat PCLS
model we have chosen ECM remodeling markers
equivalent to the markers used by Jenkins et al.
The use of an PCLS model may be an important tool
when evaluating ECM diseases such as IPF, since it is
well known that cells cultured in traditional monolayer
systems differentiate into a non in vivo-like phenotype,
and may change protein expression profile [19, 26–28].
Another advantage of the PCLS model is the in vivo-like
pathology kept within this system which may increase
the disease relevance. This may improve the success rate
when performing drug screening and raise the chance
for a new treatment to reach and be implemented in the
clinic. In the past decades over 200 drugs have been
shown to be effective in the bleomycin model, with only
2 translating into therapeutic agents for IPF. The major-
ity (95 %) of the drugs were given preventive (≤7 days
after last BLM dose), likely interfering with the inflam-
matory and early fibrogenic response [29, 30]. The US
Food and Drug Administration (FDA) has stated that
“Additional biomarkers and additional surrogate markers
are needed to guide product development” [31]. The
overall goal of using biomarkers is to improve decision-
making with regards to dosing, toxicity and treatment
time in order to save costs, which we hope can be ap-
plied in the model development.
It is well known that MMPs and other enzymes are
upregulated in IPF and play an active role in matrix re-
modeling [32, 33]. This matrix remodeling can be
assessed by biomarkers targeting the neoepitopes gener-
ated by MMP cleavage, in both formation and degrad-
ation of matrix proteins, thus the markers reflect the
tissue balance of the ECM proteins. The results pre-
sented here indicate that multiple MMPs are upregu-
lated and involved in the matrix remodeling occurring
during disease. It was shown that the system used could
be manipulated by adding treatments to the culture
medium, suggesting that the model may be used as a
system for testing ECM modifying drug candidates. It
has previously been reported, within liver and cartilage
ex vivo setups, that increasing cAMP levels (e.g. by
addition of IBMX) affects ECM remodeling [12, 34]. The
C3M biomarker has shown to be applicable in a CCl4
liver fibrosis ex vivo setup. Veidal et al. showed that
C3M was significantly elevated in supernatants from
CCl4 treated animals when compared to vehicle animals.
Furthermore by adding IBMX or GM6001 to the culture
Fig. 5 Representative pictures of Orcein Elastin staining performed on lung tissue from saline control and BLM treated animals. Elastin appears
brownish. The left section is slides from animals euthanized 7 days after last BLM or saline dose, while the right section is slides from animals
euthanized 14 days after last BLM or saline dose. Slides from BML treated animals are depicted in the upper row, while slides from saline treated
animals are depicted in the lower row. Pictures were taken at 40x magnification, and the black scale bar in the lower right corner of each picture
indicates 100 μm
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medium, they saw that the levels of C3M within the su-
pernatants from CCl4 treated animals were restored back
to the same levels as vehicle treated animals [12]. This
indicates that biomarkers are useful in a precision-cut tis-
sue slide (PCTS) setup and that these biomarkers can be
inhibited by adding treatments to the culture medium.
It has generally been accepted that collagen type I and
III are upregulated in lung tissue of IPF patients [32]. In
this paper we show that the formation (P1NP) and deg-
radation (C1M) of type I collagen are significantly in-
creased in supernatants from BLM treated animals,
when compared to saline treated animals. In the present
study, the levels of both P1NP and C1M could be sig-
nificantly inhibited by adding IBMX to culture medium,
suggesting cAMP has a role in controlling type I colla-
gen expression. The P1NP biomarker is not generated
by MMPs, hence the addition of GM6001 did not have
an effect on P1NP levels. However, the C1M biomarker
is generated from cleavage by MMP-2, -9 and -13, hence
adding GM6001 to the culture medium significantly de-
creased the levels of C1M. Taken together these data
suggest an increased turnover of type I collagen in the
lungs of animals treated with BLM, as described in the
literature but we are the first, as far as we know, to show
this turnover in an ex vivo culture setup [2, 32, 35].
The levels of type III collagen formation (iP3NP) were
significantly elevated in the supernatant of BLM treated
animals, while IBMX was able to significantly decrease
the levels. Again the iP3NP marker is not generated by
MMP cleavage, hence GM6001 had no effect as ex-
pected. Our data showed that the degradation of type III
collagen (C3M) in supernatants from BLM treated ani-
mals was 5-fold higher compared to supernatants from
vehicle animals. The levels of C3M were significantly
inhibited by adding IBMX or GM6001 to the culture
medium. This is in accordance to what was seen in the
ex vivo liver setup by Veidal et al. These data strongly
indicate a higher collagen type III turnover in animals
treated with BLM. In the PCLS model we are able to
measure upregulated turnover levels of the two most
abundant collagens, type I and III. As we are measuring
in the supernatants from cultured lung slices, we know
that the neo-epitopes are excreted from the lungs, and
not subject to background from other parts of the body.
Elastin is a protein involved in the structure, function
and elasticity of the ECM in the lungs [36]. MMP-7 is
able to degrade elastin and high levels of this enzyme
are associated with IPF [37, 38]. ELM7 has previously
been reported to be elevated in serum from IPF and
lung cancer patients [25]. Our data showed that there
are significantly increased levels of ELM7 in the super-
natants from BLM treated animals. Adding IBMX could
significantly decrease the levels, which confirms that in-
creased cAMP levels can affect the MMP expression as
seen by Karsdal et al. and Veidal et al [12, 34]. The
ELM7 fragment is MMP generated and adding
GM6001 to the culture medium could significantly de-
crease the levels as expected.
Several studies have shown that the BLM model is
known to be reversible with time [29, 39–41], where sac-
rifice of the animals 14 days after a single I.T. dose of
BLM was the most suitable. Chaudhary et al. saw that
inflammatory markers are significantly increased during
the first 9 days following BLM administration with reso-
lution of the inflammation phase around day 9 [42]. The
other interesting observation was the expression of
pro-collagen 1 mRNA which begins at day 9 and then
decreases back to baseline levels at day 21. These ob-
servations lead to the speculation that the switch be-
tween inflammation and fibrosis in the rat BLM model
occurs around day 9 [42]. Data in this paper shows that
the collagen type 1 formation (P1NP) is significantly in-
creased in the supernatants at day 7 following BLM admin-
istration when compared to vehicle animals. Interestingly,
the levels of P1NP significantly decreases when comparing
supernatants at day 14 to day 7 following BLM administra-
tion. However, the levels of P1NP in supernatants from
BLM treated animals is still significant increased at day 14
following BLM administration when compared to su-
pernatants from vehicle treated animals at day 14. The
degradation of type 1 collagen (C1M) was increased in
supernatants from BLM treated animals compared to
vehicle treated animals at day 7. The levels of C1M in
supernatants from BLM animals decreased back to the
same levels as saline treated animals at day 14. These
data suggest that the type 1 collagen balance is shifted
towards deposition of the collagen as observed by
Chaudhary et al., but it should be noted that the model
described in this paper is a double dose I.T. BLM given
two days apart.
Shahzeidi et al. saw that levels of type III procolla-
gen gene expression was increased in mice exposed
to single I.T. dose of BLM. Van Hoozen et al. was
able to measure elevated levels of type III procolla-
gen mRNA as early as 4 days after administration of
a single BLM I.T. dose in a rat model. Razzaque
et al. saw a histological increase of type III collagen
deposition over a 4 week period following a single
BLM I.T. dose in a rat model [43–45]. Our data
show that type III collagen formation is significantly
elevated 7 days following BLM administration and
then it significantly decreases 14 days following BLM
administration when compared to day 7. It should be
noted that the levels at 14 days following BLM ad-
ministration are still significantly elevated when com-
pared to vehicle. This goes well with what was seen
by Shahzeidi et al. and Van Hoozen et al., but con-
tradicts the histological findings by Razzaque et al.
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To our knowledge the turnover of type III collagen in
a BLM model has not been described. We saw the same
pattern for degradation as with the formation of type III
collagen except that there is a 15-fold increase of C3M
in supernatants from rats terminated 7 days following
BLM administration.
To our knowledge the MMP degradation of ELM7 has
not been described in a BLM model. Our findings follow
what is seen with the formation of type I and III colla-
gen. The levels are significantly elevated 7 days following
BLM administration, which decreases significantly at
14 days following BLM administration when compared
to day 7. The levels are still significantly elevated at day
14 when compared to vehicle.
Lastly we show that the lung slices were viable after
48 h of culturing and that the given treatments did not
affect the viability. Culturing of 48 h was chosen from
previous experiments, showing that viability decreases
rapidly after 48 h (data not shown). The histology shows
a higher amount of collagen and elastin in the lungs of
the animals that were given BLM compared to saline
control animals, which correlate well with the data seen
in the biomarker analyses.
Conclusion
We were able to generate a turnover profile in three of
the most affected ECM proteins in IPF, collagen type I
and III and elastin, in a BLM ex vivo model. By adding
IBMX and GM6001 we have shown that we were able to
significantly decrease the levels of the ECM biomarkers.
We then showed that these ECM markers are signifi-
cantly elevated 7 days following BLM administration and
then significantly decreased 14 days after last BLM ad-
ministration, but still significantly higher than their re-
spective saline controls.
Understanding more on the biology and the interac-
tions of all the cells in the tissue and by giving the treat-
ment after the inflammatory phase, we believe that the
risk of having false positives in a murine bleomycin
model becomes less. The markers used in the PCLS
setup are clinically validated markers shown to be upreg-
ulated in serum of IPF patients. This will increase the
chances of translation from preclinical species to human,
when screening for potential therapies.
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